Overview

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Status:
Terminated
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.
Phase:
Phase 2
Details
Lead Sponsor:
Castle Creek Pharmaceuticals, LLC
Treatments:
Diacetylrhein